The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.

Century Therapeutics, a US-based cancer treatment developer exploiting research at Harvard and Stanford universities, has filed for an initial public offering on the Nasdaq Global Select Market. The company has not yet set any financial terms and used a $100m placeholder amount. Founded in 2018 and incubated by venture capital firm Versant Ventures, Century has…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.